Business
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic
About this update from Precision Biosciences, Inc.
[{"type":"text","content":" DURHAM, N.C.--(BUSINESS WIRE)--\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022.\n\nAbout Precision BioSciences, Inc.\n\nPrecision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220801005096/en/\n\nInvestor Contact:\nMei Burris\nDirector, Investor Relations and Finance\[email protected]\n\nMedia Contact:\nMaurissa Messier\nSenior Director, Corporate Communications\[email protected]\n\nSource: Precision BioSciences, Inc.","length":2797,"tagName":"div"}]